

Successful completion of Phase 1b study of TRP-8803 (IV-infused psilocin) in obese subjects

- Three participants from an obese population safely administered TRP-8803 over 140 minutes each
- Trial commencement and completion in only one week highlights the scalability and potential of TRP-8803
- Cost-effective Phase 1b study undertaken at CMAX clinical research in Adelaide to validate TRP-8803 safety and dosing rates in obese participants
- TRP-8803 is an innovative and clinically scalable psilocin-based IV-infusion with potential neuroplastic benefits. Neuroplastic pharmaceuticals are known to cause adaptive structural and functional changes in the brain and are associated with clinical improvements in a range of psychiatric illnesses
- TRP-8803 has multiple advantages over oral psilocybin including faster onset (under 20 minutes) with precise control of the depth and duration to the psychedelic state in a commercially feasible timeframe
- Results are expected this year and will be used in development of an aggressive timeline Phase 2 clinical program
- Safe dosing of TRP-8803 in obese patients provided valuable, cost-effective human data to support dose selection for future Phase 2 trials into specific weight-related indications including Binge Eating Disorder

Melbourne, Australia – Tryptamine Therapeutics Limited ('Tryp' or the 'Company') (ASX: TYP), a clinical-stage biopharmaceutical company focused on the development of TRP-8803 (a proprietary psilocin-based, IV-infused formulation with neuroplastic benefits), is pleased to advise that it has successfully and safely completed subject dosing in its Phase 1b study into an obese population.

The open label study was undertaken at CMAX Clinical Research in Adelaide using TRP-8803 to determine if there are any differences in pharmacokinetic parameters compared to previous studied non-obese subjects (refer ASX announcement: 11 November 2024).

The trial commenced on Thursday, 21 November 2024 (refer ASX announcement: 22 November 2024) and treated three subjects with TRP-8803 over a period of 140 minutes each. Each subject progressed through the treatment well and were safely discharged shortly after study completion.

Results from the study are anticipated to be received prior to the end of the year and will support the potential application of TRP-8803 to achieve improved health outcomes in obese study participants, as well as to provide additional valuable and cost-effective data to optimise dose selection for the Company's Phase 2 clinical program using TRP-8803 in specific indications. Phase 2 clinical program planning is well advanced, and further updates are expected over the coming months.

Management commentary:

Chief Executive Officer, Mr. Jason Carroll said: *"To have completed subject dosing over such a short timeframe is a great achievement and also highlights the considerable potential for future research opportunities using TRP-8803."*



"All subjects that underwent treatment did so safely and were all discharged after the administration, marking the achievement of an important early-stage clinical objective and also confirming the potential of TRP-8803 to deliver improved health outcomes in a timely manner. We look forward to receiving the final dataset from CMAX, which will assist in our ongoing planning for Phase 2 trials to explore the efficacy of the application over specific unmet need states with large addressable market opportunities."

"The completion of subject dosing for the Phase 1b study will now allow the Company to expand its proprietary dataset across a broad patient population in a timely and cost-effective manner, as we continue to diligently execute on our comprehensive clinical development pathway for TRP-8803."

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

About Tryptamine Therapeutics Limited

Tryp Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead asset, TRP-8803, is a proprietary, scalable and innovative formulation of IV-infused psilocin (the active metabolite of psilocybin) with neuroplastic benefits. It has the potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the neuroplastic state, controlling the depth and duration of the neuroplastic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a successful clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome. Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience.

For more information, please visit www.tryptherapeutics.com.

Investor & media enquiries:

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@tryptherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

Risks associated with psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.